Soma Ghosh

2.3k citations
12 papers · 660 indexed · 1 hit paper · h-index 8

Soma Ghosh

11 papers receiving 653 citations

Hit Papers

FDA Approval Summary: Pembrolizumab for the Treatment of ...3302021202620222024100200300

Peers

Soma Ghosh
Comparison fields: 5 of 60
  • Oncology 455
  • Cancer Research 205
  • Pulmonary and Respiratory Medicine 234
  • Reproductive Medicine 41
  • Immunology 87
Replace Klaus Kluck with:
Klaus Kluck Germany
Sophia Frentzas Australia
Véronique Verrièle France
Yuzi Zhang China
Maria Vassilakopoulou Greece
Arielle L. Heeke United States
Christos Mikropoulos United Kingdom
Elena Poddubskaya Russia
Manyu Chen China
Alfredo Mellano Italy
Soma Ghosh relative to Klaus Kluck Germany Klaus Kluck's profile →
Citations per field
00.5×2.7×
Klaus Kluck · 1×
Citations per year

Countries citing papers authored by Soma Ghosh

Since Specialization
Citations

This map shows the geographic impact of Soma Ghosh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soma Ghosh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soma Ghosh more than expected).

Fields of papers citing papers by Soma Ghosh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soma Ghosh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soma Ghosh. The network helps show where Soma Ghosh may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Soma Ghosh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Soma Ghosh Line = papers co-authored together Soma Ghosh links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 202333
2 202327
3 202336
4 202334
5 20210
6
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumorsbreakdown →
2021330
7 20205
8 2020127
9 20207
10 202012
11 201843
12 20186

About Soma Ghosh

Soma Ghosh is a scholar working on Cancer Research, Oncology and Statistics and Probability, having authored 12 papers that have together received 660 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (5 papers), Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Diagnosis and Treatment (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Pancreatic and Hepatic Oncology Research (2 papers), Statistical Methods in Clinical Trials (2 papers), Genomics and Rare Diseases (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Oncology (455 citations), Cancer Research (205 citations) and Pulmonary and Respiratory Medicine (234 citations). Soma Ghosh has collaborated with scholars based in United States, Israel and Spain. Frequent co-authors include Julia A. Beaver, Richard Pazdur, Reena Philip, Steven J. Lemery, Mengdie Yuan, Leigh Marcus, Martha Donoghue, Lola A. Fashoyin‐Aje, Lisa Rodríguez and Marc R. Theoret. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026